EFFECT OF DAPAGLIFLOZIN ON THE LEVEL OF URIC ACID DURING ASYMPTOMATIC HYPERURICEMIA IN PATIENTS WITH DIABETES MELLITUS TYPE 2 AND CONCOMITANT ARTERIAL HYPERTENSION

Taking into account the adverse effect of hyperuricemia on the course of cardiovascular diseases with kidney damage as an example, which is an important problem on the background of diabetes mellitus type 2, it is expedient to study the effect on the level of uric acid in these combined pathologies using the treatment scheme (protocol) of a new class of drugs: sodium-glucose linked transporter-2 (SGLT-2) inhibitors. The aim of this research was to study the effect of Dapagliflozin on the level of uric acid in patients with diabetes mellitus type 2 (DM2) and concomitant arterial hypertension (AH) in conjunction with the dynamics of the main manifestations of both diseases. Use of SGLT-2 inhibitors e.g. Dapagliflozin in the combined treatment of patients with diabetes mellitus type 2 and concomitant arterial hypertension contributes to the reduction of uric acid levels in the blood on the background of asymptomatic hyperuricemia. 2. Use of Dapagliflozin increases the efficiency of treatment in the complex treatment of patients with diabetes mellitus type 2 and concomitant arterial hypertension with positive dynamics of carbohydrate metabolism, systolic blood pressure and improvement of the functional state of the kidneys. 3. Complex treatment with Dapagliflozin is accompanied by a decrease in the severity of correlation coefficients between uric acid levels and SBP; and between uric acid levels and HbA1C.